A role in the HBO anthology series can lead to a career renaissance or Hollywood breakthrough. So how does one make that ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Investors welcomed reports that the next wave of President Trump's tariffs will be more targeted than threatened.

Bankrupt opioid manufacturer Purdue and the Sackler family have agreed to a $7.4 billion settlement to resolve opioid claims ...

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...

Bankrupt drugmaker Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step towards finalizing a proposed opioid ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

President Trump has threatened to impose 25% tariff duty rates on “pharmaceutical” products imported into the United States. The Trump Administration does not appear to have announced the ...

“As a critical industry, any disruption to the production or distribution of pharmaceutical products can have significant cost implications for the industry and health ramifications for the ...

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...